

CURRICULUM VITAE

Prof. Dr Tomris Ozben



Personal information

Full Name: Tomris Ozben, EuSpLM, Ph.D., D.Sc., Full Professor in Medical Biochemistry
Work Address: Akdeniz University Faculty of Medicine Dept. of Clinical Biochemistry 07070 Antalya, TURKEY Tel (Office): +90 242 2496895 E-Mail: ozben@akdeniz.edu.tr

RESEARCHER ID: M-6721-2013

<http://www.researcherid.com/rid/M-6721-2013>

<http://orcid.org/0000-0002-1413-4523>

<https://www.scopus.com/authid/detail.uri?authorId=55956228900>

Education

1993	Specialisation Clinical Biochemistry	Marmara University, Medical Faculty, Istanbul, Turkey
1978	Ph.D. Biochemistry	Aegean (Ege) University, Medical Faculty, Izmir, Turkey
1975	B.Sc. Chemical Eng'g	American Robert College (Bogazici University) Istanbul, Turkey

Scientific Organisations, Societies, Committees and Councils

2023-2028	President-Elect (2023), President (2024-2025-2026) and Past-President (2027-2028) International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
2020-2025	President-Elect (2020-2021), President (2022-2023) and Past-President (2024-2025), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).
2023-	Honorary member of Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC)

2022-	Honorary Member, Slovak Society of Clinical Biochemistry (SSCB)
2018-2020	Treasurer (2 nd term), Executive Board Member , International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
2015-2017	Treasurer (1 st term), Executive Board Member , International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
2015-present	Board of Directors , IFCC Foundation for Emerging Nations (FEN).
2008-2014	Chair (two terms), IFCC Committee on Congresses & Conferences (C-CC).
2005-2007	Full Member , IFCC Committee on Congresses & Conferences (C-CC).
2003-2005	Corresponding Member , IFCC Committee on Congresses & Conferences (C-CC).
2001-2007	Member of the Advisory Board, Forum of European Societies of Clinical Chemistry and Laboratory Medicine (FESCC; IFCC-Europe).
2001-	The American Biographical Institute, The Research Board of Advisors.
2000-2003	President , Balkan Clinical Laboratory Federation (BCLF).
2003-2006	Past-President , Balkan Clinical Laboratory Federation (BCLF).
2006-present	Member, Executive Board , Balkan Clinical Laboratory Federation (BCLF).
1996-2000	Member , Advanced Courses Committee, Federation of European Biochemical Societies (FEBS).

Professional Background (Career/Employment)

1996-2000	Vice Rector of Akdeniz University, Antalya, Turkey.
2008-present	National Representative appointed by the Scientific and Technological Research Council of Turkey (TUBITAK) with the approval of the Ministry of Foreign Affairs.
1996-2000	Commission Member, the Turkish Ministry of Health for restructuring Medical Education and Teaching.
1996-2000	Member-Elect, Turkish High Educational Council.
1986-present	Founding Director & Director of Central Laboratory, Akdeniz University Hospital, Antalya, Turkey.
1997-2000	Chairman, Department of Clinical Biochemistry, Faculty of Medicine, University of Akdeniz, Antalya, Turkey.
1990-present	Full Professor, Department of Clinical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
1984-1990	Associate Professor, Department of Clinical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
1993	Specialisation in Clinical Biochemistry (exam), Marmara University, Medical Faculty, Department of Clinical Biochemistry, Istanbul, Turkey.
1983-1984	Assistant Professor, Department of Clinical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey.

1978-1983	Post-Doctoral Biochemist, Aegean (Ege) University, Medical Faculty, Izmir, Turkey.
1975-1978	Research Assistant (Ph.D., Specialisation), Department of Clinical Biochemistry, Ege University Medical Faculty, Izmir, Turkey.

Teaching Experience

Graduate

1983-present	Lecturer (Specialty, Master and Ph.D. students) in Clinical Biochemistry, Akdeniz University, Antalya, Turkey .
1983-present	Supervisor/Mentor (Specialty, Master and Ph.D. students' thesis) in Clinical Biochemistry, Akdeniz University, Antalya, Turkey .
2011-present	Lecturer , Ph.D. Course "Clinical and Experimental Medicine (CEM) –Medicina Clinica e Sperimentale". University of Modena and Reggio Emilia, Italy .
2017-present	External Examiner for M.Sci.&Ph.D. Courses in the Department of Chemical Pathology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe .

Undergraduate

1983-present	Lecturer (Clinical Biochemistry to Medical&Dentistry students)
1978-2010	Lecturer (Clinical Biochemistry to Nursing, Lab Technicians, Sports Medicine students)

Member of the Editorial Boards of Scientific Journals

2019-present	Editorial Board Member of Critical Reviews in Clinical Laboratory Sciences
2006-present	Editorial Board Member of Clinical Chemistry and Laboratory Medicine (CCLM)
1997-2006	Advisory Board Member of Clinical Chemistry and Laboratory Medicine (CCLM)
2006- present	Editorial Board Member of the Journal of Croatian Society of Medical Biochemists, Biochimia Medica
2006-present	Editorial Board Member, Journal of Medical Biochemistry
2017-present	Editorial Board Member, eJIFCC
2015-2016	Editor special issue, Oxidative Medicine and Cellular Longevity
2018-2019	Editor special issue, Oxidative Medicine and Cellular Longevity
2012-present	Editorial Board Member, Open Journal of Nephrology
2014-present	Editorial Board Member, World Journal of Methodology
1996-2002	Associate Editor for Balkan Journal of Clinical Laboratories (BJCL)

1988-1992

Editorial Board Member, **Journal of Akdeniz University**

Reviewer for the Scientific Journals

Reviewer for several journals (100-150 manuscripts / year) since 2010.

Reviewer for the Ministries and Foundations for Research Projects

2003- present	Italian Ministry for University Education and Research (MIUR-CINECA).
2005- present	The Ministry of Science and Environmental Protection of the Republic of Serbia.
2012-present	Israel Science Foundation.
1998 - present	TUBITAK- The Scientific and Technological Research Council of Turkey.

RESEARCH PROJECTS

- Coordinator /Partner of several FP6-FP7 Research Projects.
- COST EUROPEAN COOPERATION IN SCIENCE & TECHNOLOGY PROJECTS:
 1. Free Radicals in Chemical Biology (**CHEMBIORADICAL**) COST Action **CM0603**.
 2. Biomimetic Radical Chemistry. **COST Action CM1201**.
 3. Personalize Nutrition in aging Society: Redox Control of Major Age-Realted Diseases (**NutRedOx**). **COST Action CA16112**.
- Several Research, M.Sc., Ph.D., and Specialty Thesis Projects supported by TUBITAK, and/or University Research Funds.

BOOKS EDITED BY

1. OZBEN T (Edited by)
Free Radicals, Oxidative Stress and Antioxidants. Pathological and Physiological Significance.
Plenum Press, New York, USA. ISBN 0-306-45813-6, 1998.
2. TOMASI A, OZBEN T, SKULACHEV V. (Edited by)
“Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical and Clinical Aspects”
IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, Netherlands. ISBN 1 58603 243 7, 2003.
3. OZBEN T, CHEVION M. (Edited by)

“Neurodegenerative Disorders and Ageing. Fundamental Aspects, Clinical Perspectives and New Insights”

IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, Netherlands. ISBN: 1 58603 428 6, 2004.

BOOK CHAPTERS

1. OZBEN T. Pathophysiology of Cerebral Ischemia. Mechanisms Involved in Neuronal Damage in “Free Radicals, Oxidative Stress, and Antioxidants. Pathological and Physiological Significance”. Edited by TOMRIS OZBEN. ISBN:0-306-45813-6, Chapter 16, Page 163-189, 1998.

Plenum Press, New York, USA.

2. OZBEN T. Nitrogen Radicals in the Ischemic Damage of the Brain in “Free Radicals in Brain Pathophysiology”. Edited by Giuseppe Poli, Enrique Cadenas and Lester Packer.

ISBN: 0-8247-0317-0; Chapter 4, Page 77-108, 2000.

Marcel Dekker, Inc. New York, USA.

3. OZBEN T. “Non-traditional cardiovascular disease risk factors and arterial inflammatory response in end-stage renal disease” in “Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical and Clinical Aspects”. Edited by Tomasi A., Ozben T., Skulachev V.

ISBN 1 58603 243 7; Volume:344, Chapter 13, Page 136-156, 2003.

IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands.

4. OZBEN T. “Inflammatory response of the brain following cerebral ischemia” in “Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical and Clinical Aspects”. Edited by Tomasi A., Ozben T., Skulachev V.

ISBN 1 58603 243 7; Volume:344, Chapter 16, Page 186-205, 2003.

IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands.

5. OZBEN T. Effects of hemodialysis on oxidative stress and antioxidants in type II diabetic patients with uremia in “Trends in Clinical Biochemistry & Laboratory Medicine”

Edited by U. Sarma (Chief Editor). Section 9, Page 605-611, 2003 Published by Association of Clinical Biochemists of India. 2003, INDIA.

6. ASLAN M., OZBEN T. “Oxidative stres in neurodegenerative diseases” in “Neurodegenerative Disorders and Ageing. Fundamental Aspects, Clinical Perspectives and New Insights”. Edited by Ozben T, Chevion M.

IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands. ISBN: 1 58603 428 6, 2004.

7. OZBEN T. “**Oxidative stress and antioxidants in aging**” in “Neurodegenerative Disorders and Ageing. Fundamental Aspects, Clinical Perspectives and New Insights”. Edited by Ozben T, Chevion M.

IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands. ISBN: 1 58603 428 6, 2004.

8. CORT A., OZBEN T. “**Free Radicals: The Role of Antioxidants and Pro-oxidants in Cancer Development and therapy**” in Free Radicals: The Role of Antioxidants and Pro-oxidants in Cancer Development and Therapy”. Edited by William Stone. Chapter 1, Page 1-29, 2014. ISBN: 978-1-63117-179-6.
- Nova Science Publishers**, Inc. 400 Oser Avenue, Suite 1600 Hauppauge, **New York 11788 USA**. Tel: 631-299-0024 Fax: 631-299-0165 Web: www.novapublishers.com

PUBLICATIONS

(SCI-SCI-expanded)

RESEARCHER ID: M-6721-2013

URL:<http://www.researcherid.com/rid/M-6721-2013>

1. **SMART and GREEN LABORATORIES. How to implement IVDR, emerging technologies and sustainable practices in medical laboratories?**
Ozben, T
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. DOI: 10.1515/cclm-2023-0091
2. **Diagnostic quality model (DQM): an integrated framework for the assessment of diagnostic quality when using AI/ML.**
Lennerz, JK; Salgado, R; Kim, GE; Sirintrapan, SJ; Thierauf, JC; Singh, A; Indave, I; Bard, A; Weissinger, SE; Heher, YK; de Baca, ME; Cree, IA; Bennett, S; Carobene, A; Ozben, T; Ritterhouse, LL.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. DOI: 10.1515/cclm-2022-1151
3. **Editorial to celebrate the 60th anniversary of CCLM-**
Ozben, T
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. DOI: 10.1515/cclm-2023-0039-
4. **Chemical strategies for sustainable medical laboratories**
Ozben, T; Fraga-Marques, M
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. DOI: 10.1515/cclm-2022-1157
5. **Digital transformation and sustainability in healthcare and clinical laboratories**
Fraga-Marques, M, Ozben, T;
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. DOI: 10.1515/cclm-2022-1092
6. **The new, race-free, Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation to estimate glomerular filtration rate: is it applicable in Europe? A position statement by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).**
Delanaye, P; Schaeffner, E; Cozzolino, M; Langlois, M; Plebani, M; Ozben, T; Cavalier, E.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. DOI: 10.1515/cclm-2022-0928. OCT 2022.
7. **External examiners, supervisors and academicians for the international postgraduate (MSc and PhD) programmes.**
Ozben, T.
TURKISH JOURNAL OF BIOCHEMISTRY. 47 (2), pp.161-165. Jun 30 2022 |.
8. **Diagnostic proteomic markers to detect kidney diseases.**
Ozben, T; Bellei, E; Monari, E; Bergamini, S; Ferrari, A; Tomasi, A.
CLINICA CHIMICA ACTA. Volume:530, Page:S453-S453 Supplement 1. Special Issue. DOI10.1016/j.cca.2022.04.761. MAY 1, 2022.

9. Sapienic Acid Metabolism Influences Membrane Plasticity and Protein Signaling Breast Cancer Cell Lines.
Kucuksayan, E; Sansone, A; Chatgilialoglu, C; Ozben, T; Tekeli, D; Talibova, G; Ferreri, C. **CELLS**. Volume:11, Issue:2, Article Number: 225. DOI10.3390/cells11020225. JAN 2022.
10. Homocysteine (Hey) assessment to predict outcomes of hospitalized Covid-19 patients: a multicenter study on 313 Covid-19 patients.
Ponti, G; Roli, L; Oliva, G; Manfredini; Trenti, T; Kaleci, S; Iannella, R; Balzano, B; Coppola, A; Fiorentino, G; Ozben, T; Delli Paoli, V; Debbia, D; De Santis, E; Pecoraro, V; Melegari, A; Sansone, Mr; Lugara, M; Tomasi, A. **CLINICAL CHEMISTRY AND LABORATORY MEDICINE**. Volume:59, Issue: 9, Page: E354-E357. DOI10.1515/cclm-2021-0168. AUG 26 2021.
11. Diagnostic proteomic biomarkers to detect kidney diseases.
Ozben, T; Bellei, E ; Monari, E; Bergamini, S; Pini, La; Tomasi, A. **FEBS OPEN BIO**. Volume11, Page39-40. Supplement1. Meeting Abstract S-06.3-1. Jul 2021
12. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
Kucuksayan, E; Bozkurt, F; Yilmaz, MT; Sircan-Kucuksayan, A; Hanikoglu, A; Ozben, T. **SCIENTIFIC REPORTS**. 11 (1):13027. Jun 22 2021 DOI10.1038/s41598-021-92447-x
13. COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence.
Ponti, G; Pastorino, L; Manfredini, M; Ozben, T; Oliva, G; Kaleci, S; Iannella, R; Tomasi, A. **JOURNAL OF CLINICAL LABORATORY ANALYSIS**. 35(7): e23798. 2021 Jul; DOI10.1002/jcla.23798.
14. Plasma thiol/disulphide homeostasis changes in patients with relapsing-remitting multiple sclerosis.
Serkan Ozben, Ertan Kucuksayan, Mesrure Koseoglu, Ozcan Erel, Salim Neselioglu, Tomris Ozben. **INTERNATIONAL JOURNAL OF CLINICAL PRACTICE**. 75(7): e14241. July 2021. DOI10.1111/ijcp.14241
15. Plasma thiol/disulphide homeostasis changes in patients with restless legs syndrome.
Kucuksayan, Ozben, S; Tuac, St; Koseoglu, M; Erel, O; Neselioglu, S; Ozben, T. **CLINICAL CHEMISTRY AND LABORATORY MEDICINE**. 59(7):1257-1265. DOI10.1515/cclm-2020-1659, 2021.
16. Liquid biopsy with cell free DNA: new horizons for prostate cancer.
Ponti, Giovanni; Maccaferri, Monia; Percesepe, Antonio; Tomasi, Aldo; Ozben, Tomris. **CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES** early access. AUG 2020.
17. Plasma copeptin levels in patients with multiple sclerosis.
Koseoglu, Mesrure; Ozben, Serkan; Gozubatik-Celik, Gokcen; Tutuncu, Mesude; Kucuksayan, Ertan; Hanikoglu, Aysegul; Atakli, Dilek; Ozben, Tomris. **JOURNAL OF CLINICAL NEUROSCIENCE** Volume: 78 Pages: 143-146 Published: AUG 2020.
18. Biomarkers associated with COVID-19 disease progression.
Ponti, Giovanni; Maccaferri, Monia; Ruini, Cristel; Ruini, Cristel; Tomasi, Aldo; Ozben, Tomris. **CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES** Volume: 57 Issue: 6 Special Issue: SI Pages: 389-399 Published: AUG 17 2020
19. Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes.
Hanikoglu, Aysegul; Kucuksayan, Ertan; Hanikoglu, Ferhat; Ozben, Tomris; Menounou, Georgia; Sansone, Anna; Chatgilialoglu, Chrys ; Di Bella, Giuseppe; Ferreri, Carla.

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY Volume: 98 Issue: 3
Pages: 131-138 Published: MAR 2020.

- 20. Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy**
Hanikoglu, Aysegul; Ozben, Hakan; Hanikoglu, Ferhat; Ozben, Tomris.
CURRENT MEDICINAL CHEMISTRY Volume: 27 Issue: 13 Pages: 2118 - 2132 Published: 2020 .
- 21. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease.**
Ozben, Tomris; Ozben, Ozben, Serkan.
CLINICAL BIOCHEMISTRY Volume: 72 Pages: 87-89 Published: OCT 2019.
- 22. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.**
Ponti, G ; Maccaferrri, M; Manfredini, M; Micali, S; Torricelli, F; Milandri, R; del Prete, C; Ciarrocchi, A; Ruini, C; Benassi, L; Bettelli, S; Kaleci, S; Ozben, T; Tomasi, A.
CLINICA CHIMICA ACTA. Volume: 497 Pages: 76-80 Published: OCT 2019.
- 23. Modulation of Oxidative Stress: Pharmaceutical and Pharmacological Aspects.**
Smith, Robert E.; Ozben, Tomris; Sas, Luciano.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY Volume: 2019 Article Number: 6380473 Published: JUL 3 2019.
- 24. Effects of bleomycin and N-acetyl-L-cysteine on the MAPK signalling pathway in testicular germ-cell tumor.**
Donmez, A. Cort; Ozben, T.; Melchiorre, M.; Chatgilialoglu, C; Ferreri, C; Sansone, A.
FEBS OPEN BIO Volume: 9 Supplement: 1 Pages: 337-337 Meeting Abstract: P-35-060 Published: JUL 2019.
- 25. Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes.** Hanikoglu, A; Kucuksayan, E; Hanikoglu, F; Ozben, T; Menounou, G; Sansone, A; Chatgilialoglu, C; Di Bella, G; Ferreri, C.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY Volume: 19 Issue: 15 Pages: 1899-1909 Published: 2019.
- 26. Urinary proteomics in biomarker discovery of kidney-related disorders: diabetic nephropathy and drug-induced nephrotoxicity in chronic headache.**
E. BELLEI, E. MONARI, S. BERGAMINI, L. ALBERTO PINI, A. TOMASI, T. OZBEN.
eJIFCC. Page:290-298, Volume: 29, No:4, ISSN:1650-3414. December 2018.
- 27. Seminal Cell-Free DNA Assessment as a Novel Prostate Cancer Biomarker.**
PONTI, G., MACCAFERRRI, M., MANDRIOLI, M., MANFREDINI, M., MICALI, S., COTUGNO, M., BIANCHI, G., OZBEN, T., PELLACANI, G., DEL PRETE., TOMASI, A.
PATHOLOGY & ONCOLOGY RESEARCH. Volume: 24 Issue: 4 Pages: 941-945 Published: OCT 2018.
- 28. Oxidative stress and voltage-gated sodium channel activity in human breast cancer cells.**
CORT, A., OZBEN, T., DJAMGOZ, M. B. A.
FEBS OPEN BIO. Volume: 8 Pages: 359-360 Published: JUL 2018.
- 29. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients.**
PONTI, G., MACCAFERRRI, M., MANFREDINI, M., KALECI, S., MANDRIOLI, M., PELLACANI, G., OZBEN, T., DEPENNI, R., BIANCHI, G., PIROLA, GM., TOMASI, A.
CLINICA CHIMICA ACTA. Volume: 479 Pages: 14-19 Published: APR 2018.
- 30. Plasma copeptin levels in patients with restless legs syndrome.**
TUAC, S. T., OZBEN, S., BITNEL, M.K., KOKSAL, A., KUCUKSAYAN, E., HANIKOGLU, A., OZBEN, T..

ACTA NEUROLOGICA SCANDINAVICA. Volume: 137 Issue: 3 Pages: 316-320 Published: MAR 2018.

31. **Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.** HANIKOGLU, AYSEGUL; HANIKOGLU, FERHAT; OZBEN, TOMRIS. **CURRENT PROTEIN & PEPTIDE SCIENCE.** Volume: 19 Issue: 3 Pages: 333-340 Published: 2018.
32. **Effects of melatonin in cancer: potential mechanisms.** OZBEN, T., HANIKOGLU, A., KUCUKSAYAN, E., AKDUMAN, R. C. **ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY.** Volume 18, Issue 7, 2018. DOI : 10.2174/1871520617666171121120223.
33. **New combination strategy of doxorubicin and epoxomicin in biocompatibility: Biodegradable polymeric nanoparticles increase apoptosis in breast cancer cells.** KUCUKSAYAN, E., BOZKURT, F., OZBEN, T., CICEK, P.K., HANIKOGLU, A., YILMAZ, M.T. **JOURNAL OF BIOTECHNOLOGY.** Volume: 256 Supplement: S Pages: S36-S36 Published: AUG 30 2017.
34. **Effects of Long- and Short-term Darbepoetin-alpha Treatment on Oxidative Stress, Inflammation and Endothelial Injury in Apo E Knockout Mice.** OZDEMIR, E. D., HANIKOGLU, A., CORT, A., OZBEN, B., SULEYMANLAR, G., OZBEN, T. **ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE.** Volume: 26 Issue: 4 Pages: 635-643 Published: JUL 2017.
35. **Hybrid Compounds as Multitarget Directed Anticancer Agents.** KUCUKSAYAN, ERTAN; OZBEN, TOMRIS. **CURRENT TOPICS IN MEDICINAL CHEMISTRY** Volume: 17 Issue: 8 Pages: 907-918 Published: 2017.
36. **Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer.** PONTI, G., MACCAFERRI, M., DEPENNI, R., MANDRIOLI, M., PELLACANI, G., MANFREDINI, M., OZBEN, T., RUINI, C., IATTONI, E., CERIOLI, D., CASCINU, S., TOMASI, A. **ANNALS OF ONCOLOGY.** Volume: 27 Supplement: 4 M09 Published: SEP 21 2016.
37. **Research update for articles published in EJCI in 2014.** MARIA AGRA, ROSA; AL-DAGHRI, NASSER M.; BADIMON, LINA; *et al.* **EUROPEAN JOURNAL OF CLINICAL INVESTIGATION** Volume: 46 Issue: 10 Pages: 880-894 Published: OCT 2016.
38. **AISF position paper on liver transplantation and pregnancy. Women in Hepatology Group, Italian Association for the Study of the Liver (AISF).** ALISI, ANNA; BALSANO, CLARA; BERNABUCCI, VERONICA; *et al.* Group Author(s): Women Hepatology Grp; Italian Assoc Study Liver AISF. **DIGESTIVE AND LIVER DISEASE.** Volume: 48 Issue: 8 Pages: 860-868 Published: AUG 2016.
39. **Natural redox modulators of oxidative stress and chemoresistance in cancer therapy: beneficial versus deleterious effects.** OZBEN, T., CORT, A. **FEBS JOURNAL** Volume: 283 Special Issue: SI Supplement: 1 Pages: 47-47 S09.044001 Published: SEP 2016.
40. **Bleomycin-induced trans lipid formation in liposomes.** CORT, A., OZBEN, T., SANSONE, A., BARATA-VALLEJO, S., CHATGILIALOGLU, C., FERRERI, C. **FEBS JOURNAL.** Volume: 283 Special Issue: SI Supplement: 1 Pages: 290-290 P03033-004 Published: SEP 2016.

- 41. Plasma thiol levels in patients with prostate cancer.**
 HANIKOGLU, A., HANIKOGLU, F., KUCUKSAYAN, E., ALISIK, M., GOCENER, A.A., EREL, O., BAYKARA, M., PONTI, G., TOMASI, A., OZBEN, T.
FEBS JOURNAL Volume: 283 Special Issue: SI Supplement: 1 Pages: 410-410 Meeting Abstract: P09044-107 Published: SEP 2016.
- 42. Effects of bleomycin and antioxidants on the fatty acid profile of testicular cancer cell membranes.**
 CORT, A., OZBEN, T., MELCHIORRE, M., CHATGILIALOGLU, C., FERRERI, C. SANSONE, A. **BIOCHIMICA ET BIOPHYSICA ACTA.** 1858:434-441; 2016.
- 43. Dynamic thiol/disulphide homeostasis before and after radical prostatectomy in patients with prostate cancer.**
 HANIKOGLU, F., HANIKOGLU, A., KUCUKSAYAN, E., ALISIK, M., GOCENER, A.A., EREL, O., BAYKARA, M., CUOGHI, A., TOMASI, A., OZBEN, T.
FREE RADICAL RESEARCH Volume: 50 Supplement: 1 Pages: S79-S84 Published: 2016
- 44. Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants.**
 CORT, A., OZBEN, T., SASO, L., DE LUCA, C., KORKINA, L.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY. Article Number: 4251912. DOI: 10.1155/2016/4251912. Published: 2016.
- 45. Modulation of Oxidative Stress: Pharmaceutical and Pharmacological Aspects.**
 KORKINA, L., OZBEN, T., SASO, L.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY. Article Number: 6023417. DOI: 10.1155/2016/6023417. Published: 2016
- 46. Natural product modulators to overcome multidrug resistance in cancer.**
 CORT, A., OZBEN, T.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL 67 (3): 411-423, 2015.
- 47. Increased plasma soluble tumor necrosis factor receptor-1 and myeloperoxidase activity in patients with obstructive sleep apnea syndrome.**
 HANIKOGLU F., HUSEYINOGLU N., OZBEN S., CORT A., OZDEM S., OZBEN T. **INTERNATIONAL JOURNAL OF NEUROSCIENCE.** 125 (9): 655-662; 2015.
- 48. Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis.**
 HANIKOGLU F., CORT A., OZBEN H., HANIKOGLU A., OZBEN T.
ANTICANCER AGENTS IN MEDICINAL CHEMISTRY. 15 (4), 527-533, 2015.
- 49. Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with upregulation of death receptors.**
 TIMUR M., CORT A., OZDEMIR E., SARIKCIOGLU S.B., SANLIOGLU S., SANLIOGLU A.D., OZBEN T.
ANTICANCER AGENTS IN MEDICINAL CHEMISTRY. 15 (1): 99-106, 2015.
- 50. Antioxidant Supplementation on Cancer Risk and Concurrent Use of Antioxidants during Cancer Therapy: An Update.**
 OZBEN T.
CURRENT TOPICS IN MEDICINAL CHEMISTRY. 15 (2): 170-178, 2015.
- 51. Bleomycin-induced trans lipid formation in cell membranes and in liposome models.**
 CORT, A., OZBEN, T., SANSONE, A., BARATA-VALLEJO, S., CHATGILIALOGLU, C., FERRERI, C.
ORGANIC & BIOMOLECULAR CHEMISTRY. 13 (4): 1100-1105, 2015.
- 52. Advanced oxidation protein products and ischemia modified albumin in obstructive sleep apnea.**
 OZBEN, S., HUSEYINOGLU, N., HANIKOGLU,F., GUVENC,T.S., YILDIRIM,B.Z., CORT,A., OZDEM, S., OZBEN, T.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 44 (11):1045-52, 2014.

- 53. Membrane trans fatty acids in human testicular cancer cell membranes: the signal transduction pathways and effects of chemotherapeutics and antioxidants.**
OZBEN, T., CORT, A., MELCHIORRE, M., CHATGILALOGLU, C., ; FERRERI, C.
FEBS JOURNAL Volume: 281 Special Issue: SI Supplement: 1 Pages: 203-203 SUN-406
Published: SEP 2014.
- 54. Inflammation: an important parameter in the search of prostate cancer biomarkers.**
BERGAMINI, S., BELLEI, E., REGGIANI BONETTI, L., MONARI, E., CUOGHI, A., BORELLI, F., SIGHINOLFI, M. C., BIANCHI, G., OZBEN, T., TOMASI, A.
PROTEOME SCIENCE 12; 32-44, 2014.
- 55. Low serum copeptin levels in patients with obstructive sleep apnea.**
OZBEN, S., GUVENC, T. S., HUSEYINOGLU, N., SANIVAR, H. S., HANIKOGLU, F., CORT, A., OZBEN, T.
SLEEP AND BREATHING. 17(4);1187-1192, 2013.
- 56. N-Acetyl-L-Cysteine inhibits bleomycin induced apoptosis in malignant testicular germ cell tumours.**
KUCUKSAYAN, ERTAN; CORT, AYSEGUL; TIMUR, MUJGAN; OZDEMIR, EVRIM; YUCEL, GULTEKIN; OZBEN, TOMRIS.
JOURNAL OF CELLULAR BIOCHEMISTRY 114(7):1685-1694, 2013.
- 57. Effects of curcumin on bleomycin-induced apoptosis in human malignant testicular germ cells.**
CORT, A., TIMUR, M., OZDEMIR, E., OZBEN, T.
J. PHYSIOL BIOCHEM. 69(2):289-296, 2013.
- 58. Cisplatin loaded PMMA: mechanical properties, surface analysis and effects on Saos-2 cell culture.**
OZBEN, H., ERALP, L., BAYSAL, G., CORT, A., SARKALKAN, N., OZBEN, T. ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA 47(3):184-192; 2013.
- 59. Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache.**
ELISA BELLEI, EMANUELA MONARI, AURORA CUOGHI, STEFANIA BERGAMINI, SIMONA GUERZONI, MICHELA CICCARESE, TOMRIS OZBEN, ALDO TOMASI AND LUIGI ALBERTO PINI.
THE JOURNAL OF HEADACHE AND PAIN 14:6, 2013.
- 60. Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry.**
OZBEN, T.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 51(1): 157–176, 2013.
- 61. Effects of N-acetyl-L-cysteine on bleomycin induced oxidative stress in malignant testicular germ cell tumors.**
CORT, A., TIMUR, M., OZDEMIR, E., OZBEN, T.
BIOCHIMIE Dec; 94(12):2734-2739, 2012.
- 62. Effects of N-acetylcystein on bleomycin induced apoptosis in malignant testicular germ cell tumors.**
CORT, A., TIMUR, M., OZDEMIR, E., KUCUKSAYAN, E., ASLAN, M., OZBEN, T.
JOURNAL OF PHYSIOLOGICAL BIOCHEMISTRY Oct;68(4):555-562, 2012.
- 63. Evaluation of the Correlation of Urine Isoprostane F2-alpha Levels with Functional Capacity and Left Ventricular Systolic and Diastolic Functions in the Patients with Dilated Cardiomyopathy.**
DOGAN, U., DURSUN, E., YALCINKAYA, S., OZBEN, T.

64. Quantification of p-cresol sulphate in human plasma by selected reaction monitoring.
CUOGHI A., CAIAZZO M., BELLEI E., MONARI E., BERGAMINI S., PALLADINO G., OZBEN T., TOMASI A.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY 404:2097–2104, 2012.
65. Effects of curcumin on bleomycin induced oxidative stress in malignant testicular germ cell tumours.
CORT, A., OZDEMIR, E. TIMUR, M., OZBEN, T.
MOLECULAR MEDICINE REPORTS. 6 (4):860-866, 2012.
66. Oxidative stress, antioxidants and apoptosis: impact on cancer therapy.
OZBEN, T.
FEBS JOURNAL Volume: 279 Special Issue: SI Supplement: 1 Pages: 29-29 Published: SEP 2012.
67. Effect of N-acetyl cysteine on human testicular cancer cell membrane lipid profile.
CORT, A., OZBEN, T., MELCHIORRE, M., CHATGILIALOGLU, C., FERRERI, C. **FEBS JOURNAL** Volume: 279 Special Issue: SI Supplement: 1 Pages: 125-125 Published: SEP 2012.
68. Is serum adiponectin level a marker for mortality in intensive care patients?
HANIKOGLU, F., UZUN, G., CENGIZ, M., DONMEZ, L., OZDEM, S., OZBEN, T.
FEBS JOURNAL Volume: 279 Special Issue: SI Supplement: 1 Pages: 546-547 Published: SEP 2012.
69. The effects of N-Acetyl-L-Cysteine on Bleomycin induced apoptosis were determined in malignant testicular germ cell tumours by Flow Cytometry.
KUCUKSAYAN, E., CORT, A., YUCEL, S.G., OZBEN, T.
EUROPEAN JOURNAL OF CANCER Volume: 48 Supplement: 5 Pages: S222-S222 920 Published: JUL 2012
70. Synergistic anticancer activity of curcumin and bleomycin: An in vitro study using human malignant testicular germ cells.
CORT, A., TIMUR, M., OZDEMIR, E., KUCUKSAYAN, E., OZBEN, T.
MOL. MED. REPORT. 5 (6):1481-1486, 2012.
71. Apoptotic effects of curcumin and bleomycin alone or in combination on malignant testicular germ cells.
CORT, A., KUCUKSAYAN, E., OZBEN, T.
CANCER RESEARCH Volume: 72 Supplement: 8 4910 Published: APR 15 2012.
72. Aspirin resistance in patients with acute ischemic stroke.
OZBEN S, OZBEN B, TANRIKULU AM, OZER F, OZBEN T.
JOURNAL OF NEUROLOGY. 258(11):1978-1986, 2011.
73. Aspirin resistance in patients with chronic renal failure.
TANRIKULU, A. M., OZBEN, B., KOC, M., PAPILA-TOPAL, N., OZBEN, T., CAYMAZ, O. **JOURNAL OF NEPHROLOGY**. Volume: 24 Issue: 5 Pages: 636-646 Published: SEP-OCT 2011.
74. Bleomycin increases trans lipid isomers in human testicular cancer cell membrane.
CORT, A., OZBEN, T., KUCUKSAYAN, E., MELCHIORRE, M., CHATGILIALOGLU, C., FERRERI, C.
FEBS JOURNAL Volume: 278 Special Issue: SI Supplement: 1 Pages: 201-201 Published: JUN 2011.
75. Optimizing protein recovery yield from serum samples treated with beads technology.

BELLEI E, MONARI E, BERGAMINI S, OZBEN T, TOMASI A.
ELECTROPHORESIS. Volume: 32 Issue: 12 Pages: 1414-1421 Published: JUN 2011.

76. N-acetyl-L-Cysteine inhibits bleomycin induced apoptosis in human testicular cancer cells.
CORT, A., OZBEN, T., TIMUR, M., OZDEMIR, E., ASLAN, M.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE Volume: 49 Supplement: 1
Pages: S231-S231 Published: MAY 2011.
77. Detection of serum protein profile changes in atherosclerosis.
DURSUN, E., OZBEN, B., MONARI, E., CUOGHI, A., BERGAMINI, S., TOMASI, A., OZBEN, T.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE Volume: 49 Supplement: 1
Pages: S263-S263 Published: MAY 2011.
78. Oxidative stress and antioxidants in cancer.
OZBEN, TOMRIS.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE Volume: 49 Suppl: 1 Pages:
S263-S263 Published: MAY 2011.
79. High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins.
BELLEI, E., BERGAMINI, S., MONARI, E., FANTONI, L. I., CUOGHI, A., OZBEN, T. TOMASI,
A.
AMINO ACIDS. Jan; 40(1):145-56, 2011.
80. Aspirin resistance in patients with chronic renal failure.
SADIC, B. OZBEN; TANRIKULU, M. A., KOC, M., OZBEN, T., CAYMAZ, O.
EUROPEAN HEART JOURNAL Volume: 31 Suppl: 1 Pages: 966-966 Published: SEP 2010
81. Aspirin resistance in hypertensive patients.
OZBEN B, TANRIKULU AM, OZBEN T, CAYMAZ O.
JOURNAL OF CLINICAL HYPERTENSION Volume: 12 Issue: 9 Pages: 714-720 Published:
SEP 2010.
82. Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: Effect of darbepoetin treatment.
DURSUN, E., MONARI, E., CUOGHI, A., BERGAMINI, S., OZBEN, B., SULEYMANLAR, G.,
TOMASI, A. AND OZBEN, T.
ACTA HISTOCHEMICA, Volume: 112 Issue: 5 Pages: 432-443 Published: 2010.
83. Proteomic profiling in apolipoprotein E-deficient mice during atherosclerosis progression.
DURSUN, E., OZBEN, B., MONARI, E., CUOGHI, A., TOMASI, A. AND OZBEN, T.
ACTA HISTOCHEMICA, Volume: 112 Issue: 2 Pages: 178-188 Published: 2010.
84. Acute effects of hemodialysis on oxidative stress parameters in chronic uremic patients: comparison of two dialysis membranes.
VARAN HI, DURSUN B, DURSUN E, OZBEN T, SULEYMANLAR G.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE
Volume: 3 Pages: 39-45 Published: 2010.
85. Proteomic profiling during atherosclerosis progression: Effect of nebivolol treatment.
OZBEN, B., DURSUN, E., MONARI, E., CUOGHI, A., BERGAMINI, S., TOMASI, A. and OZBEN,
T.
MOLECULAR AND CELLULAR BIOCHEMISTRY Volume: 331 Issue: 1-2 Pages: 9-17
Published: NOV 2009.
86. The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress.
DURSUN, B., DURSUN, E., SULEYMANLAR, G., OZBEN, B., CAPRAZ, I., APAYDIN, A. AND
OZBEN, T.

JOURNAL OF DIABETES AND ITS COMPLICATIONS Volume: 23 Issue: 4 Pages: 257-264
Published: JUL-AUG 2009.

87. **Diverse effects of antioxidants on the cytotoxicity of chemotherapeutic drugs.**
OZBEN, TOMRIS.
UBMB LIFE Volume: 61 Issue: 3 Pages: 284-284 Published: MAR 2009.
88. **Effects of Diet and Gemfibrozil on Posttransplant Hyperlipidemia in Renal Transplant Recipients.**
SAPAN, M., OZBEN, B., YAKUPOGLU, G., SULEYMANLAR, G., OZBEN, T.
JOURNAL OF INVESTIGATIVE MEDICINE Volume: 57 Issue: 2 Pages: 456-459
Published: FEB 2009.
89. **Hydrogen Peroxide Induces Apoptosis in Human Testicular Cancer Cells by Activating the Caspase Cascade.**
CORT, A., OZBEN, T., TIMUR, M., OZDEMIR, E., ASLAN, M.
FREE RADICAL BIOLOGY AND MEDICINE. Volume:47 Pages: S167-S168 Published: 2009.
90. **Effect of oxidative stress on carotid artery intima-media thickness in diabetic patients.**
DURSUN, E., DURSUN, B., SULEYMANLAR, G., OZBEN, B., CAPRAZ, I., APAYDİN, A., OZBEN, T. **ATHEROSCLEROSIS Suppl.** Volume: 9 Issue: 1 Pages: 73-73 Published: MAY 2008.
91. **Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis.**
DURSUN, B., DURSUN, E., SULEYMANLAR, G., OZBEN, B., CAPRAZ, I., APAYDİN, A., OZBEN, T. **NEPHROLOGY DIALYSIS TRANSPLANTATION**. Volume:23 Issue:5 Pages:1697-1703 Published: MAY 2008
92. **Are uremia, diabetes, and atherosclerosis linked with impaired antioxidant mechanisms?**
DURSUN, B., DURSUN, E., CAPRAZ, I., OZBEN, T., APAYDIN, A. AND SULEYMANLAR, G.
JOURNAL OF INVESTIGATIVE MEDICINE. Volume: 56 Issue: 2 Pages: 545-552
Published: FEB 2008.
93. **Oxidative stress and apoptosis: impact on cancer therapy.**
OZBEN T.
JOURNAL OF PHARMACEUTICAL SCIENCES Volume: 96 Issue: 9 Pages: 2181-2196
Published: SEP 2007.
94. **Intima-media thickness correlates with oxidative stress in chronic kidney diseases.**
OZBEN, T.; DURSUN, E.; SULEYMANLAR, G., DURSUN, B.
CLINICAL CHEMISTRY Volume: 53 Issue: 6 Suppl. Pages: A29-A29 A91 Published: JUN 2007.
95. **Concurrent use of antioxidants in cancer therapy: An update.**
OZBEN T.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY.Volume:2 Issue:6 Pages:931-9 Published: 2006.
96. **The relation of cytokines, serum insulin and insulin resistance with the progression free survival and overall survival of metastatic breast cancer patients.**
OZBEN, T.; BOZCUK, H.; USLU, G., AKAN, I., SAVAS, B.
CLINICAL CHEMISTRY Volume: 52 Issue: 6 Suppl: S Pages: A173-A173 E28
Published:JUN 2006.
97. **Diverse effects of antioxidants on the cytotoxicity of chemotherapeutic drugs.**
OZBEN, T.; AKBAS, H. S.; TİMUR, M., AKAN, I., AKAN, S.
CLINICAL CHEMISTRY Volume: 52 Issue: 6 Pages: A173-A173 E29 Published: JUN 2006.
98. **The role of antioxidants in the cytotoxicity of chemotherapeutic drugs.**

OZBEN, T.; AKBAS, H.; AKAN, I.; AKAN, S., TİMUR, M.
FEBS JOURNAL Volume: 273 Suppl: 1 Pages: 17-17 Published: JUN 2006.

99. The effect of different dialysis membranes on lipid and protein oxidation in hemodialysis patients.
DURSUN, E.; TIMUR, M.; VARAN, H. I., SULEYMANLAR, G., OZBEN, T.
FEBS JOURNAL Volume: 273 Supplement: 1 Pages: 150-150 Published: JUN 2006.
100. Mechanisms and strategies to overcome multiple drug resistance in cancer.
OZBEN T.
FEBS LETTERS Volume: 580 Issue: 12 Pages: 2903-2909 Published: MAY 22 2006.
101. Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: An in vitro study.
YILDIZ M, CELIK-OZENCI C, AKAN S, AKAN I, SATI L, DEMİR R, SAVAS B, OZBEN T, SAMUR M, OZDOGAN M, ARTAC M, BOZCUK H.
CELL BIOLOGY INTERNATIONAL. Volume: 30 Issue: 3 Pages: 278-282 Published: MAR 2006
102. Effect of pentylenetetrazol-induced epileptic seizure on the antioxidant enzyme activities, glutathione and lipid peroxidation levels in rat erythrocytes and liver tissues.
AKBAS SH, YEGIN A, OZBEN T.
CLINICAL BIOCHEMISTRY. Volume: 38 Issue: 11 Pages: 1009-1014 Published: NOV 2005.
103. Effects of MK-801 on nitrite and cGMP levels during focal cerebral ischemia in rats.
OZBEN T, BALKAN E, BALKAN S, SERTESER M, GUMUSLU S.
NITRIC OXIDE. Volume: 13 Issue: 3 Pages: 210-215 Published: NOV 2005.
104. Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus.
DURSUN E, DURSUN B, SULEYMANLAR G, OZBEN T.
ACTA DIABETOLOGICA. Volume: 42 Issue: 3 Pages: 123-128 Published: OCT 2005.
105. Protein oxidation in Type 2 diabetic patients on hemodialysis.
DURSUN E, TIMUR M, DURSUN B, SULEYMANLAR G, OZBEN T.
JOURNAL OF DIABETES AND ITS COMPLICATIONS. Volume: 19 Issue: 3 Pages: 142-146 Published: MAY-JUN 2005.
106. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
AKBAS, SH; TIMUR, M; OZBEN, T
CLINICA CHIMICA ACTA Volume: 355 Pages: S308-S308 Published: MAY 2005.
107. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
OZBEN, T; BOZCUK, H; USLU, G., AKAN, I.
CLINICA CHIMICA ACTA Volume: 355 Pages: S137-S138 Published: MAY 2005.
108. Effects of N-acetylcysteine and buthionine sulfoximine on doxorubicin resistance in parental and MRP1 transfected HEK293 cells.
OZBEN, T; AKAN, I; AKAN, S., AKCA, H., SAVAS, B.
CLINICA CHIMICA ACTA Volume: 355 Pages: S437-S437 Published: MAY 2005.
109. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
AKBAS SH, TIMUR M, OZBEN T.
JOURNAL OF SURGICAL RESEARCH Volume: 125 Issue: 1 Pages: 49-55 Published: MAY 1, 2005.
110. Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine.

AKAN I, AKAN S, AKCA H, SAVAS B, OZBEN T.
CANCER CELL INTERNATIONAL Volume: 5 Article Number: 22 Published: 2005.

111. The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line. TIMUR M, AKBAS SH, OZBEN T.
ACTA BIOCHIMICA POLONICA Volume: 52 Issue: 4 Pages: 897-902 Published: 2005.
112. Carbonyl stress in chronic renal failure: the effect of haemodialysis.
DURSUN E, DURSUN B, SULEYMANLAR G, OZBEN T.
ANNALS OF CLINICAL BIOCHEMISTRY Volume: 42 Pages: 64-66 Part: 1 Published: JAN 2005.
113. N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance.
AKAN I, AKAN S, AKCA H, SAVAS B, OZBEN T.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATIONS Volume:4 Issue:10 Pages:683-689 Published: OCT 2004.
114. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
BOZCUK H, USLU G, SAMUR M, YILDIZ M, OZBEN T, OZDOGAN M, ARTAC M, ALTUNBAS H, AKAN I, SAVAS B.
CYTOKINE Volume: 27 Issue: 2-3 Pages: 58-65 Published: JUL 21 2004
115. Reactive oxygen and nitrogen species in Alzheimer's disease.
ASLAN M, OZBEN T.
CURRENT ALZHEIMER RESEARCH Volume: 1 Issue: 2 Pages: 111-119 Published: MAY 2004.
116. Pathology of cerebral ischaemia. Mechanisms involved in neuronal damage.
OZBEN T.
YUGOSLAV MEDICAL BIOCHEMISTRY 22(2):85-93, 2003.
117. Rapid production of chicken egg yolk antibodies against multidrug resistance-associated protein 1 (MRP-1).
OZBEN T, AKAN I.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY Volume:34 Issue:3-4 Pages:195-199, 2004.
118. Oxidants in receptor tyrosine kinase signal transduction pathways.
ASLAN M, OZBEN T.
ANTIOXIDANTS & REDOX SIGNALING Volume:5 Issue: 6 Pages: 781-788 Published: DEC 2003.
119. Interleukin-1beta, tumor necrosis factor-alpha, and nitrite levels in febrile seizures.
HASPOLAT S, MIHCI E, COSKUN M, GUMUSLU M, OZBEN T, YEGIN O.
JOURNAL OF CHILDHOOD NEUROLOGY Volume:18 Issue:2 Pages:118-118 Published:FEB 2003.
120. N-acetylcysteine induces MRP1 drug resistance in HEK293 cells
OZBEN, T., AKAN, I; AKAN, SY., AKCA, H.
FREE RADICAL RESEARCH Volume: 37 Pages: 42 Published: 2003
121. Secretory phospholipase A2 and phospholipids in neural membranes in an experimental epilepsy model.
YEGIN A, AKBAS SH, OZBEN T, KORGUN DK.
ACTA NEUROLOGICA SCANDINAVICA 106(5):258-62, 2002.
122. Effect of hemodialysis on the oxidative stress and antioxidants.
DURSUN E, OZBEN T, SULEYMANLAR G, DURSUN B, YAKUPOGLU G..

CLINICAL CHEMISTRY AND LABORATORY MEDICINE 40(10): 1009-1013, 2002.

- 123. The effects of NMDA receptor antagonist MK-801 on lipid peroxidation during focal cerebral ischemia in rats.**
SERTESER M, OZBEN T, GUMUSLU S, BALKAN S, BALKAN E.
PROGRESS IN NEUROPSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY
26(5):871-7, 2002.
- 124. Lipid peroxidation in rat brain during focal cerebral ischemia: prevention of malondialdehyde and lipid conjugated diene production by a novel antiepileptic, lamotrigine.**
SERTESER M, OZBEN T, GUMUSLU S, BALKAN S, BALKAN E.
NEUROTOXICOLOGY 23(1):111-119, 2002.
- 125. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.**
AKBAS SH, OZBEN T, ALPER O, UGUR A, YUCEL G, LULECI G.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE 39(6):487-90, 2001.
- 126. Lipid profile and apolipoprotein E genotyping in stroke: A case-control study.**
SERTESER M, VISVIKIS S, OZBEN T, HERBETH T, BALKAN S, SIEST G.
NEUROSCIENCE-NET 3:10015, 2001.
- 127. Alterations of antioxidant enzymes and oxidative stress markers in aging.**
KASAPOGLU M, OZBEN T.
EXPERIMENTAL GERONTOLOGY 36(2):209-220, 2001.
- 128. Biochemical evidence of crossed cerebellar diaschisis in terms of nitric oxide indicators and lipid peroxidation products in rats during focal cerebral ischemia.**
SERTESER M, OZBEN T, GUMUSLU S, BALKAN S, BALKAN E.
ACTA NEUROLOGICA SCANDINAVICA 103(1):43-48, 2001.
- 129. Plasma antioxidant status in sulfur dioxide exposed rats.**
GUMUSLU S, SERTESER M, AGAR A, KUCUKATAY V, YARGICOGLU P., OZBEN T.
BALKAN JOURNAL OF CLINICAL LABORATORY 4(3-4):5-9, 1997.
- 130. Inhibitory role of N^ω-nitro-L-arginine methyl ester(L-NAME), a potent nitric oxide synthase inhibitor on brain malondialdehyde and conjugated diene levels during focal cerebral ischemia in rats.**
GUMUSLU S, SERTESER M, OZBEN T, BALKAN S, BALKAN E.
CLINICA CHIMICA ACTA 267(2): 213-223, 1997.
- 131. Effects of lamotrigine on brain nitrite and cGMP levels during focal cerebral ischemia in rats.**
BALKAN S, OZBEN T, BALKAN E, OGUZ N, SERTESER M, GUMUSLU S.
ACTA NEUROLOGICA SCANDINAVICA 95(3): 140-146, 1997.
- 132. The effects of nitric oxide synthase inhibitor, L-NAME on NO production during focal cerebral ischemia in rats: Could L- NAME be the future treatment of sudden deafness?**
BALKAN E, BALKAN S, OZBEN T, SERTESER M, GUMUSLU S, OGUZ N.
INTERNATIONAL JOURNAL OF NEUROSCIENCE 89: 61-77, 1997.
- 133. Evaluation of different glycemic screening parameters in Diabetes Mellitus with or without complications: The importance of glycohemoglobin.**
YEGIN A, OZBEN T.
TURKISH JOURNAL OF BIOCHEMISTRY 22(3):8-11, 1997.
- 134. The effects of detergents on t-butyl hydroperoxide-induced chemiluminescence.**
GUMUSLU S, ERKILIC A, YUCEL G, SERTESER M, OZBEN T.
INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH 26(3):203-206, 1996.
- 135. Serum lipoprotein(a) level in patients with chronic renal insufficiency.**

YAKUPOGLU G, SULEYMANLAR G, OZBEN T, SAPAN M, ERSOY FF.
JOURNAL OF TURKISH NEPHROLOGY, DIALYSIS AND TRANSPLANTATION 5: 11-15,1996.

136. Vitamin E levels in thyroid diseases.
ERKILIC A, ERKILIC M, GUMUSLU S, YUCEL G, OZBEN T.
TURKISH JOURNAL OF MEDICAL SCIENCES 26(1):7-9, 1996.
137. Serum and urine malondialdehyde levels in NIDDM patients with and without hyperlipidemia.
NACITARHAN S, OZBEN T, TUNCER N.
FREE RADICAL BIOLOGY AND MEDICINE 19:893-896, 1995.
138. Event related potentials in hypertriglyceridemia.
AGAR A, YARGICOGLU P, OZBEN T.
INTERNATIONAL JOURNAL OF NEUROSCIENCE 83:103-110, 1995.
139. ERP spectral analysis of cholesterol rich patients.
AGAR A, YARGICOGLU P, OZBEN T, NUZUMLALI D, OGUZ Y.
INTERNATIONAL JOURNAL OF NEUROSCIENCE 83:93-101, 1995.
140. Serum glycated lipoproteins in type II diabetic patients with and without complications.
YEGIN A, OZBEN T.
ANNALS OF CLINICAL BIOCHEMISTRY 32:459-463, 1995.
141. Plasma and urine sialic acid in non-insulin dependent diabetes mellitus.
OZBEN T, NACITARHAN S, TUNCER N.
ANNALS OF CLINICAL BIOCHEMISTRY 32:303-306, 1995.
142. The effects of streptozocin induced diabetes on renal plasma flow.
ERKILIC BAYKAL A, ERKILIC M, OZBEN T.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES 103:367-372, 1995.
143. Plasma and urine malondialdehyde levels in non-insulin dependent diabetic patients with and without microalbuminuria.
OZBEN T, NACITARHAN S, TUNCER N.
INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH 25:162-164, 1995.
144. Glycation of lipoproteins and accelerated atherosclerosis in non-insulin dependent diabetes mellitus.
YEGIN A, OZBEN T, YEGIN H.
INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH 25:157-161, 1995.
145. The effect of hypercholesterolemia on event-related brain potentials (P3).
YARGICOGLU P, AGAR A, OGUZ Y, NUZUMLALI D, OZBEN T.
Turkish Journal of Medical Science 23:1-5, 1995.
146. Serum lipoproteins in renal transplant patients. The effect of cyclosporine on lipoprotein(a).
SULEYMANLAR G, OZBEN T, SAPAN B, YILMAZ H, YAKUPOGLU G, KARPUZOGLU T.
TRANSPLANTATION PROCEEDINGS 26(5):2637-2638, 1994.
147. Elevated serum and urine sialic acid levels in renal diseases.
OZBEN T.
ANNALS OF CLINICAL BIOCHEMISTRY 28:44-48, 1991.
148. Morphine increases plasma immunoreactive atrial natriuretic peptide levels in humans.
OGUTMAN C, OZBEN T, SADAN G, TRAKYA A, ISBIR M.
ANNALS OF CLINICAL BIOCHEMISTRY 27:21-24, 1990.

- 149. Serum bone Gla-protein(osteocalcin) in rheumatoid arthritis.**
OZBEN T, GUNDOGAR AG, ALICIGUZEL Y.
NAGOYA MEDICAL JOURNAL 34(2):101-107, 1990.
- 150. Effects of clonidine on pancreatic purinoceptor mediated secretions of insulin and glucagon.**
SADAN G, OZBEN T, AYNACIOGLU S.
JOURNAL OF BIOCHEMISTRY 15(1):9-18, 1990.
- 151. Biliary lipid composition and gallstone formation of rabbits fed soy protein, cholesterol, casein and modified casein.**
OZBEN T.
BIOCHEMICAL JOURNAL 263:293-296, 1989
- 152. The quantitative determination of thyroid gland phospholipids by thin-layer chromatography.**
MENTES G, OZBEN T, ERLACIN S, ERSOZ B.
JOURNAL OF BIOCHEMISTRY 3(1,2):311-326, 1978.

PUBLICATIONS

(National Journals)

More than 100 manuscripts have been published in national journals.

CONGRESSES ATTENDED

Invited speaker in more than 200 congresses/workshops/courses organized worldwide to deliver oral communications and plenary lectures in the last two decades.